The latest hematology research from leading journal Leukemia

Advertisement See how droplets are guiding precision medicine  Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring. Is your lab using this tool to its full potential? See how a promising new technology lets you give clinicians insights that can guide personalized cancer treatments. TABLE OF CONTENTS Volume 32, Issue 10 In this issue Review Article Article Brief Communication Correction Also new AOP Advertisement   Now Enrolling - Clinical studies for oral pracinostat in Acute Myeloid Leukemia (AML) Patients Unfit for Induction Chemotherapy and in Myelodysplastic Syndromes (MDS) trials Pracinostat is an investigational agent not approved for commercial use by the FDA or any other regulatory agency worldwide PRAN-US-0024   Review Article Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines? Nazanin Aghel, Diego Hernan Delgado & Jeffrey Howard Lipton Leukemia 2018 32 :2095 - 2104; September 10, 2018; 10.1038/s41375-018-0247-1 Abstract | Full Text Dysregulated iron metabolism in polycythemia vera: etiology and consequences Yelena Z. Ginzburg, Maria Feola, Eran Zimran, Judit Varkonyi, Tomas Ganz et al. Leukemia 2018 32 :2105 - 2116; July 24, 2018; 10.1038/s41375-018-0207-9 Abstract | Full Text Article Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia Rebeqa Gunnarsson, Sebastian Dilorenzo, Kristina B Lundin-Ström, Linda Olsson, Andrea Biloglav et al. Leukemia 2018 32 :2117 - 2125; March 12, 2018; 10.1038/s41375-018-0092-2 Abstract | Full Text Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia Melissa A. Burns, Zi Wei Liao, Natsuko Yamagata, Gayle P. Pouliot, Kristen E. Stevenson et al. Leukemia 2018 32 :2126 - 2137; March 20, 2018; 10.1038/s41375-018-0097-x Abstract | Full Text Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia Phuong Cao Thi Ngoc, Shi Hao Tan, Tze King Tan, Min Min Chan, Zhenhua Li et al. Leukemia 2018 32 :2138 - 2151; March 26, 2018; 10.1038/s41375-018-0110-4 Abstract | Full Text MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences Alberto L′Abbate, Doron Tolomeo, Ingrid Cifola, Marco Severgnini, Antonella Turchiano et al. Leukemia 2018 32 :2152 - 2166; February 22, 2018; 10.1038/s41375-018-0033-0 Abstract | Full Text Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012 Mareike Rasche, Martin Zimmermann, Lisa Borschel, Jean-Pierre Bourquin, Michael Dworzak et al. Leukemia 2018 32 :2167 - 2177; February 22, 2018; 10.1038/s41375-018-0071-7 Abstract | Full Text Demethylator phenotypes in acute myeloid leukemia Andrew D. Kelly, Jozef Madzo, Priyanka Madireddi, Patricia Kropf, Charly R. Good et al. Leukemia 2018 32 :2178 - 2188; March 07, 2018; 10.1038/s41375-018-0084-2 Abstract | Full Text RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia S. Rudat, A. Pfaus, Y. Y. Cheng, J. Holtmann, J. M. Ellegast et al. Leukemia 2018 32 :2189 - 2202; March 22, 2018; 10.1038/s41375-018-0102-4 Abstract | Full Text Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients Anna Ravn Landtblom, Hannah Bower, Therese M.-L. Andersson, Paul W. Dickman, Jan Samuelsson et al. Leukemia 2018 32 :2203 - 2210; January 30, 2018; 10.1038/s41375-018-0027-y Abstract | Full Text Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma Fernando Gallardo, Joan Bertran, Erika López-Arribillaga, Jéssica González, Silvia Menéndez et al. Leukemia 2018 32 :2211 - 2223; February 22, 2018; 10.1038/s41375-018-0066-4 Abstract | Full Text Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma Xiaohui Zhang, Hans C. Lee, Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin et al. Leukemia 2018 32 :2224 - 2239; March 27, 2018; 10.1038/s41375-018-0044-x Abstract | Full Text Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria Eli Muchtar, Angela Dispenzieri, Nelson Leung, Martha Q. Lacy, Francis K. Buadi et al. Leukemia 2018 32 :2240 - 2249; February 20, 2018; 10.1038/s41375-018-0060-x Abstract | Full Text Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma Yi Hu, Jianhong Lin, Hua Fang, Jing Fang, Chen Li et al. Leukemia 2018 32 :2250 - 2262; March 22, 2018; 10.1038/s41375-018-0104-2 Abstract | Full Text Brief Communication Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study Jorne Lionel Biccler, Lene Sofie Granfeldt Østgård, Marianne Tang Severinsen, Claus Werenberg Marcher, Peter Møller et al. Leukemia 2018 32 :2263 - 2303; February 23, 2018; 10.1038/s41375-018-0054-8 Abstract | Full Text The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity Elena Masselli, Cecilia Carubbi, Benedetta Cambò, Giulia Pozzi, Giuliana Gobbi et al. Leukemia 2018 32 :2266 - 2270; March 06, 2018; 10.1038/s41375-018-0088-y Abstract | Full Text Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients Alexander Höllein, Sabine Jeromin, Manja Meggendorfer, Annette Fasan, Niroshan Nadarajah et al. Leukemia 2018 32 :2270 - 2274; March 06, 2018; 10.1038/s41375-018-0086-0 Abstract | Full Text U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions Ayalew Tefferi, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling et al. Leukemia 2018 32 :2274 - 2278; February 27, 2018; 10.1038/s41375-018-0078-0 Abstract | Full Text Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia Paolo Strati, Alessandra Ferrajoli, William G. Wierda, Nitin Jain, Philip A. Thompson et al. Leukemia 2018 32 :2278 - 2281; February 20, 2018; 10.1038/s41375-018-0059-3 Abstract | Full Text Germline alterations in a consecutive series of acute myeloid leukemia Ulla Wartiovaara-Kautto, Elina A. M. Hirvonen, Esa Pitkänen, Caroline Heckman, Janna Saarela et al. Leukemia 2018 32 :2282 - 2285; April 10, 2018; 10.1038/s41375-018-0049-5 Abstract | Full Text Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia Ya-Zhen Qin, Xiao-Jun Huang & Hong-Hu Zhu Leukemia 2018 32 :2285 - 2287; March 14, 2018; 10.1038/s41375-018-0095-z Abstract | Full Text Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy Laura N Eadie, Timothy P Hughes & Deborah L White Leukemia 2018 32 :2288 - 2291; March 23, 2018; 10.1038/s41375-018-0101-5 Abstract | Full Text First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells M. Hojjat-Farsangi, A. H. Daneshmanesh, A. S. Khan, J. Shetye, F. Mozaffari et al. Leukemia 2018 32 :2291 - 2295; March 27, 2018; 10.1038/s41375-018-0113-1 Abstract | Full Text Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases Constance Baer, Christian Pohlkamp, Claudia Haferlach, Wolfgang Kern & Torsten Haferlach Leukemia 2018 32 :2295 - 2298; March 30, 2018; 10.1038/s41375-018-0119-8 Abstract | Full Text Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients Inge G. P. Geelen, Fredrik Sandin, Noortje Thielen, Jeroen J. W. M. Janssen, Mels Hoogendoorn et al. Leukemia 2018 32 :2299 - 2303; April 19, 2018; 10.1038/s41375-018-0136-7 Abstract | Full Text Correction Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences Alberto L'Abbate, Doron Tolomeo, Ingrid Cifola, Marco Severgnini, Antonella Turchiano et al. Leukemia 2018 32 :2304 - 2304; July 09, 2018; 10.1038/s41375-018-0177-y Abstract | Full Text Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma P. G. Richardson, C. C. Hofmeister, N. S. Raje, D. S. Siegel, S. Lonial et al. Leukemia 2018 32 :2305 - 2305; September 14, 2018; 10.1038/s41375-018-0235-5 Abstract | Full Text Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL C. Prieto, B. López-Millán, H. Roca-Ho, R. W. Stam, D. Romero-Moya et al. Leukemia 2018 32 :2306 - 2306; September 14, 2018; 10.1038/s41375-018-0236-4 Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. This email has been sent to edgeblog.alerts.2011.001@gmail.com. If you no longer wish to receive the email alerts from Leukemia click here to unsubscribe . If you wish to discontinue all email services from Nature Research please click here to unsubscribe . For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.